Autopsy report · NCT01095887

Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

“Poor enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Kidney Transplant

Interventions

Eculizumab

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Use of Prokinetics in Early Enteral Feeding in Preterm Infants
  “very poor enrollment” (96% match in meaning)
• CPT-3 in Normal Pressure Hydrocephalus
  “Inadequate enrollment” (91% match in meaning)
• Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects
  “Low enrollment” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.